Cyproterone acetate, an antiandrogenic steroid with inhibitory effects on gonadotropin secretion, was given to 13 girls and 6 boys with precocious puberty for periods of 1-3 years in a daily dose of 70 mg/m2 body surface area. Treatment was started at a mean chronologic age of 6.65 years in girls and 6.21 years in boys.
Introduction
tale, the problem o C short adult stature has not been solved since these drugs fail to normalize final adult Precocious puberty is a condition with considerable height [4, 5, 11, 15, 211 . impact on the patient and his family. UnEortunately, After antiandrogenic compounds were introduced there is as yet no satisfactory hormonal treatment; alinto clinical medicine, their use seemed indicated in though the development of secondary sex characterisboys with precocious puberty, at a stage when androtics and menstruation are inhibited to some extent by gen secretion is increased in early childhood. Cypromedroxyprogesterone acetate or chlormadinone aceterone acetate (1,2-a-methylene-6-chloro-4,6-pregnadi-ene-17-~-01-3,20-dione-l7-~-acetate), a steroid which was synthesized by Mliechert and Neumann [26] in 1965, appeared to be applicable to both boys and girls with precocious puberty, inasmuch as animal experiments had demonstrated an inhibitory effect on gonadotropin secretion in addition to its direct antiandrogenic properties [16, 221. I n men its suppressive effect on libido has already been well documented [lo 12, 171 . T h e present report analyzes our experience with cyproterone acetate in the treatment of precocious puberty in both sexes since 1967.
Patients and Methods
A diagnosis of precocious puberty was made when the first pubertal signs appeared before the age of 8 years in girls or 9 years in boys. Thirteen girls and 6 boys formed the treatment group (see Tables I and 11 ). I n a. 11 treated girls cornification of the basal cells of the vaginal mucosa was demonstrated. Congenital adrenal hyperplasia was excluded in all cases by steroid determinations in urine (normal 17-ketosteroids and pregnanetriol for bone age and absence of pregnanetrio- percentile charts [25] . Standard deviation scores (SD T h e data from patients treated for a minimum consecscores) [24] were calculated using the data for normal utive period of 1 year were compared with those from Zurich children [3] . T h e height SD score at a given untreated cases of precocious puberty and those treated chronologic or bone age was calculated by subtracting with other hormonal preparations. For comparison of from the measurement of height the normal mean at -the clinical results, 9 untreated girls and 1 untreated the age at which the measurement was taken and boy were available (Tables I11 and IV) . For growth dividing this difference by the SD. Bone age was detercomparison 12 untreated girls (8 idiopathic, 3 cerebral, mined by the method of Greulich and Pyle [7] , cor-1 Albright syndrome) and 10 untreated boys (8 idio- rected for Ziirich children [3] . Because at present the Zurich standards extend only to 12 years [3] , the nearly identical standards of Tanner et a1 [25] were used in the calculation of height SD score for bone age in all cases.
T h e tables of Bayley and Pinneau [I] were used in the prediction of adult height. Where possible, the predicted or measured adult height of an individual was compared with the expected height calculated from the height of the parents ("target height") [23] . T h e mean parental height was adjusted for the sex of the child by adding 12.5 cm to the height of the mother before calculating the mean in the case of a boy, and by subtracting 12.5 cm from the height of the father in the case of a girl, 12.5 cm being the 
difference between men and women on their respective definitely decreased or disappeared when present at 50th percentiles. I n order to obtain the SD score ol the the start of treatment. Cyproterone acetate hat1 a suppredicted or measured adult height, the difference bepressive effect on sexuality in all cases. It did not retween this and the "target height" was divided by the verse deepening of the voice. Testicular volumes are appropriately reduced SD of 4.25 cm 1231. Testicular shown in Figure 1 . They remained unchanged during volumes were compared to normal Zurich standards therapy. Chronological age, years
Clinical Elfects
T h e clinical response to treatment in 13 girls is summarized in Table V . Menstruation ceased in four girls and was partially suppressed in two who continued to have occasional spotting. Five of the seven girls who were premenarchal at the start of treatment had rare vaginal bleeding during therapy. A reduction i n breast size was noted in nine cases. Reduction in pubic and axillary hair was observed in most cases and acne disappeared or diminished when present. T h e clinical effects in the six boys are shown in Table VI. T h e size of the penis decreased in most cases; pubic hair decreased in three boys; axillary hair and acne Figures 2a and 3a show the course of linear growth in untreated cases of precocious puberty; an abnormal growth spurt caused maximal deviation of height at about 8 years in girls and 6 years in boys. After this age, statural growth decreased and stopped after epiphyseal fusion at around 12 years i n girls and 10 years in boys. Linear growth during cyproterone acetate treatment is represented in Figures 2b and 3b . There is no obvious difference between the growth of treated and untreated patients. Figure 4 shows the height SD score for chronologic age. T h e mean of the individual values of the treated cases was centered on the mean chronologic age at the start of treatment, which was 6.65 years for girls and 6.21 years for boys. Thus, the values to the right of the vertical axis represent years of therapy. Untreated cases were plotted as a group at their actual chronologic ages. T h e mean height SD score for treated cases increased both for boys and girls and that for untreated cases fell, but none of the differences between the groups reached statistical significance at the 5% level. Figure 5 sho~is the bone age SD score in the two groups. Both girls and boys in the untreated groups had more advanced bone ages at the time of start of treatment than the treated patients, but cyproterone acetate did not reduce the excessive bone age advancement.
Eflects on Growth
I n 18 untreated girls, for whom these data were available, the difference of the mean height SD score for bone age at the start of observation and at a mean time with cyproterone acetate; ---: without cyproterone acetate. Differences between the groups a t 0 to +3 years are statistically insignificant (P > 0.05).
----n = 5 8 of 6.7 years later was t0.07 (Table VII) ; in the untreated boys it was -0.29 over 3.5 years. T h e comparable figures in the treated groups were -0.24 over 2.6 years in girIs and -0.27 over 3.4 years in boys. None of these values differ significantly either from 0 or from each other. Untreated boys and girls had an earlier onset of puberty than treatkd cases tr able VII). found either between or within groups. There was a marked sex difference in the mean deficit of measured adult height, which was 7.2 cm in girls and 16.8 cm in boys. No clinical side effects of therapy were noted. I n contrast to medroxyprogesterone acetate, which was used in previous years, glucocorticoid effects such as striae and obesity [5] were not observed. Adrenal suppression, which has been described with medroxyprogesterone acetate in man [14, 201 and with high doses of cyproterone acetate in animal experiments [6, 271, has not been investigated in our patients, but is unlikely with the dosage used.
T h e inhibition of testicular growth after the bone age of normal puberty indicates the probable suppression of pituitary gonadotropin secretion, although there are no comparable data from untreated cases. I n one boy of the present series, a gradual reduction in plasma testosterone to prepubertal levels (2,620 to 140 ng/100 ml) was documented within a year of institution of cyproterone acetate therapy, which also suggests gonadotropin suppression.
In contrast to its beneficial clinical effects, cyproterone acetate had no effect on growth. T h e aim of treatment would be to increase adult stature by diminishing the advancement of skeletal maturation without impairing linear growth. Thus, the height SD score for bone age should improve. In fact, no significant differences between treatment and control groups 6 . a: height prediction in girls allowing for parental heights were found, and there was no effect on height pre-(difference from "target height" [23] poor correlation with adult height [4] .
years:
-h -I +I +h +i +A +A adult Despite the obvious clinical effects, which are attributed to the antigonadotropin and antiandrogenic properties of the drug, there is no evidence of a delaying effect on bone maturation. This is at variance with previous reports [2, 8, 13, 191 . We attribute this to three factors: we have analyzed data from a larger number of patients over a prolonged period of time, a large control group clarifying the natural history of precocious puberty has been included, and different analytic methods have been used.
Our findings are somewhat contradictory to observations from animal experiments: in normal rats, cyproterone acetate retarded cartilage ossification, but led ultimately to decreased bone length [9] and in testosterone-treated rats, short final length was prevented by the simultaneous administration of cyproterone acetate [9] . In this respect, it is of interest that height prediction in untreated patients does not change significantly after diagnosis and that growth and skeletal maturation after this time proceed concomitantly. This and the experience with rats may indicate that the desired inhibiting effect on bone maturation might possibly be obtained by earlier and/or more vigorous treatment only.
I t is concluded that cyproterone acetate in a daily dosage of 70 mg/m2 has no major advantage in comparison with drugs used previously such as medroxyprogesterone acetate. Both drugs have considerable beneficial effects on the clinical signs of precocious puberty, but are without demonstrable effects on growth. Although the effects of cyproterone acetate on the gonads seem to be fully reversible in men [IS] , experience in females and in boys is still limited.
Cyproterone acetate, an antiandrogenic compound with inhibitory effect on the gonadotropin secretion, was administered to 13 girls and 6 boys with precocious puberty for periods of 1 year to more than 3 years in a daily dose of 70 mg/m2 by mouth. This drug proved to have beneficial effects on the clinical signs of precocious puberty and no side effects were noted. T h e effects on growth were analyzed by comparing the data of height, bone age, height for bone age, and height prediction in treated cases with those obtained from 21 girls and 11 boys with precocious puberty who did not receive cyproterone acetate. Inasmuch as no differences were found, it is concluded that cyproterone acetate in the dosage used is without effect on growth.
